The study demonstrates that the extract supports glycemic control in prediabetic and diabetic patients by increasing GLP-1 levels and decreasing systemic inflammation.
A recent study1 found that a patented extract of lemon-based flavonoids, called Eriomin from Ingredients by Nature (Montclair, CA), may benefit two significant areas of prediabetes management. In the study, 30 subjects were given either placebo of 200 mg per day of Eriomin for 12 weeks, then after a two-week washout switched interventions for another 12 weeks. Researchers assessed biochemical, metabolic, inflammatory, blood pressure, anthropometry, and dietary parameters at the beginning and end of each intervention period.
Results showed that supplementation with Eriomin significantly decreased blood glucose (−5%), homeostasis model assessment of insulin resistance (−11%), glucagon (−13%), interleukin-6 (−14%), tumor necrosis factor alpha (−20%), alkaline phosphatase (−13%), and increased glucagon-like peptide 1 (GLP-1) by (17%). This demonstrates that the extract supports glycemic control in prediabetic and diabetic patients by increasing GLP-1 levels and decreasing systemic inflammation.
“We are thrilled to see that Eriomin continues to show its benefits towards managing prediabetes, a prominent health concern for today’s consumer,” said Rob Brewster, president of Ingredients by Nature, in a press release. “One in three Americans have prediabetes, and 400 million people worldwide are already prediabetic. This study further reveals Eriomin’s ability to be a proactive and multifunctional approach to prediabetes management.”
This latest study validates previous results that demonstrated Eriomin’s blood glucose benefits at doses of 200 mg and up, in prediabetic patients. “We plan to conduct additional studies with Eriomin to see how it can further benefit those who need alternatives to pharmaceuticals when controlling their blood sugar levels,” said Brewster.